Evolution of the Brazilian Drug Control System: Case Study of ADB-FUBIATA, a Psychotropic NPS

Emerging trends in drugs, addictions, and health Pub Date : 2024-12-01 DOI:10.1016/j.etdah.2023.100103

M.L.S. Macedo, L. dos Santos Lopes, G.H. Giudice, R. de Morais Souza

{"title":"Evolution of the Brazilian Drug Control System: Case Study of ADB-FUBIATA, a Psychotropic NPS","authors":"M.L.S. Macedo, L. dos Santos Lopes, G.H. Giudice, R. de Morais Souza","doi":"10.1016/j.etdah.2023.100103","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>The New Psychoactive Substances (NPS) market is very dynamic, requiring new legislative approaches to tackle the drug problem. Brazil has improved the Drug Scheduling System, making the process more agile, which allows fast scheduling of NPS. The Working Group conceived between Anvisa and the Ministry of Justice, brings together experts of health regulation, forensics, law enforcement and drug policy, and posed a significant role in evolving the Brazilian Drug Control System.</div></div><div><h3>Methods</h3><div>The Working Group created an online form to facilitate and accelerate drug notification from brazilian Police. Through this tool, in 11/19/2021, Anvisa received a communication regarding the synthetic cannabinoid ADB-FUBIATA, a psychotropic NPS. This molecule was also reported in Brazilian Early Warning System.</div></div><div><h3>Results</h3><div>ADB-FUBIATA is now a prohibited substance. The ban took place about two months after the drug notification.</div></div><div><h3>Conclusions</h3><div>The NPS market continues to shift and diversify at an alarming speed, posing a significant risk to public health and a challenge to drug policy. Brazil has made substance scheduling faster through the implementation of an online notification form and the establishment of an Early Warning System. ADB-FUBIATA is an example of improved communication between those involved with the drug problem.</div></div>","PeriodicalId":72899,"journal":{"name":"Emerging trends in drugs, addictions, and health","volume":"4 ","pages":"Article 100103"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Emerging trends in drugs, addictions, and health","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667118223000545","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

The New Psychoactive Substances (NPS) market is very dynamic, requiring new legislative approaches to tackle the drug problem. Brazil has improved the Drug Scheduling System, making the process more agile, which allows fast scheduling of NPS. The Working Group conceived between Anvisa and the Ministry of Justice, brings together experts of health regulation, forensics, law enforcement and drug policy, and posed a significant role in evolving the Brazilian Drug Control System.

Methods

The Working Group created an online form to facilitate and accelerate drug notification from brazilian Police. Through this tool, in 11/19/2021, Anvisa received a communication regarding the synthetic cannabinoid ADB-FUBIATA, a psychotropic NPS. This molecule was also reported in Brazilian Early Warning System.

Results

ADB-FUBIATA is now a prohibited substance. The ban took place about two months after the drug notification.

Conclusions

The NPS market continues to shift and diversify at an alarming speed, posing a significant risk to public health and a challenge to drug policy. Brazil has made substance scheduling faster through the implementation of an online notification form and the establishment of an Early Warning System. ADB-FUBIATA is an example of improved communication between those involved with the drug problem.

查看原文本刊更多论文

巴西药物管制系统的演变：ADB-FUBIATA的案例研究，精神药物NPS

新精神活性物质（NPS）市场非常活跃，需要新的立法方法来解决药物问题。巴西改进了药物调度系统，使这一过程更加灵活，从而可以快速调度NPS。该工作组由Anvisa和司法部构想，汇集了卫生法规、法医学、执法和药物政策方面的专家，并在巴西药物管制系统的发展中发挥了重要作用。方法工作组创建了一个在线表格，以方便和加快巴西警方的药物通报。通过该工具，Anvisa于2021年11月19日收到了关于合成大麻素ADB-FUBIATA（一种精神药物NPS）的通信。该分子在巴西早期预警系统中也有报道。结果：adb - fubiata现已被列为违禁物质。该禁令是在药物通知后大约两个月实施的。NPS市场继续以惊人的速度转变和多样化，对公共卫生构成重大风险，对药物政策构成挑战。巴西通过实施在线通知表格和建立早期预警系统，加快了物质调度速度。ADB-FUBIATA是改善与毒品问题有关的人之间沟通的一个例子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Emerging trends in drugs, addictions, and health Pharmacology, Psychiatry and Mental Health, Forensic Medicine, Drug Discovery, Pharmacology, Toxicology and Pharmaceutics (General)

CiteScore

2.40

自引率

0.00%

发文量